EUVIMEDEUVIMED entdecken
Crossref

Clinical translation of a novel FAPI dimer [68Ga]Ga-LNC1013

Yue Tan, Jian Li, Tianzhi Zhao, Ming Zhou, Kehuang Liu, Shijun Xiang, Yongxiang Tang, Vivianne Jakobsson, Pengfei Xu, Xiaoyuan Chen, Jingjing Zhang iD

European Journal of Nuclear Medicine and Molecular Imaging · 2024-07 · 51 (9) · 2761-2773

DOI: 10.1007/s00259-024-06703-z ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 02.04.2024. Verfasst von Yue Tan und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diagnostic Radiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 119074, Singapore. Hauptthemen laut MEDLINE: Gallium Radioisotopes. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: Singapore Ministry of Education (FY2022) Tier 1 Grant.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Fibroblast activation protein (FAP) has emerged as a highly promising target for cancer diagnostic imaging and targeted radionuclide therapy. To exploit the therapeutic potential of suitably radiolabeled FAP inhibitors (FAPIs), this study presents the design and synthesis of a series of FAPI dimers to increase tumor uptake and retention. Preclinical evaluation and a pilot clinical PET imaging study were conducted to screen the lead compound with the potential for radionuclide therapy. METHODS: Three new FAPI dimers were synthesized by linking two quinoline-based FAPIs with different spacers. The in vitro binding affinity and preclinical small animal PET imaging of the compounds were compared with their monomeric counterparts, FAPI-04 and FAPI-46. The lead compound, [68Ga]Ga -LNC1013, was then evaluated in a pilot clinical PET imaging study involving seven patients with gastrointestinal cancer. RESULTS: The three newly synthesized FAPI homodimers had high binding affinity and specificity in vitro and in vivo. Small animal PET imaging and biodistribution studies showed that [68Ga]Ga-LNC1013 had persistent tumor retention for at least 4 h, also higher uptake than the other two dimers and the monomer counterparts, making it the lead compound to enter clinical investigation. In the pilot clinical PET imaging study, seven patients were enrolled. The effective dose of [68Ga]Ga-LNC1013 was 8.24E-03 mSv/MBq. The human biodistribution of [68Ga]Ga-LNC1013 demonstrated prominent tumor uptake and good tumor-to-background contrast. [68Ga]Ga-LNC1013 PET imaging showed potential in capturing primary and metastatic lesions and outperforming 18F-FDG PET in detecting pancreatic and esophageal cancers. The SUVmax for lesions with [68Ga]Ga-FAPI-46 decreased over time, whereas [68Ga]Ga-LNC1013 exhibited persistently high tumor uptake from 1 to 4 h post-injection. CONCLUSION: Dimerization is an effective strategy to produce FAPI derivatives with favorable tumor uptake, long tumor retention, and imaging contrast over its monomeric counterpart. We demonstrated that [68Ga]Ga-LNC1013, the lead compound without any piperazine moiety, had superior diagnostic potential over [68Ga]Ga-FAPI-46 and 18F-FDG, suggesting the future potential of LNC1013 for radioligand therapy of FAP-positive cancers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gallium RadioisotopesHumansAnimalsMiceCell Line, TumorFemaleTissue DistributionPositron-Emission TomographyMaleDimerizationRadiopharmaceuticalsMiddle AgedTranslational Research, BiomedicalAgedMembrane ProteinsEndopeptidasesQuinolinesFibroblast Activation Protein Alpha

Stichwörter der Autor:innen

68GaDimerizationFibroblast activation protein (FAP)PET imagingPiperazine

Substanzen

Gallium RadioisotopesRadiopharmaceuticalsMembrane ProteinsEndopeptidasesQuinolinesFibroblast Activation Protein Alpha68Ga-FAPI

Autor:innen und Institutionen

  • Department of Diagnostic Radiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 119074, Singapore.
  • Department of Nuclear Medicine, Xiangya Hospital, Central South University, Changsha, People's Republic of China.
  • Clinical Imaging Research Centre, Centre for Translational Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 117599, Singapore.
  • Nanomedicine Translational Research Program, NUS Center for Nanomedicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 117597, Singapore.
  • Department of Nuclear Medicine, The First Affiliated Hospital of Shandong Second Medical University, Weifang, China. pengfeixucsu@outlook.com.
  • Department of Diagnostic Radiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 119074, Singapore. chen.shawn@nus.edu.sg.

ORCID-Profile: Jingjing Zhang

Förderung

  • Singapore Ministry of Education (FY2022) Tier 1 Grant

Zitieren

APA

Tan, Y., Li, J., Zhao, T., Zhou, M., Liu, K., Xiang, S., Tang, Y., Jakobsson, V., Xu, P., Chen, X., & Zhang, J. (2024). Clinical translation of a novel FAPI dimer [68Ga]Ga-LNC1013. European Journal of Nuclear Medicine and Molecular Imaging, 51(9), 2761-2773. https://doi.org/10.1007/s00259-024-06703-z

Vancouver

Tan Y, Li J, Zhao T, Zhou M, Liu K, Xiang S, et al. Clinical translation of a novel FAPI dimer [68Ga]Ga-LNC1013. European Journal of Nuclear Medicine and Molecular Imaging. 2024;51(9):2761-2773. doi:10.1007/s00259-024-06703-z

BibTeX
@article{Tan2024,
  author = {Tan, Yue and Li, Jian and Zhao, Tianzhi and Zhou, Ming and Liu, Kehuang and Xiang, Shijun and Tang, Yongxiang and Jakobsson, Vivianne and Xu, Pengfei and Chen, Xiaoyuan and Zhang, Jingjing},
  title = {Clinical translation of a novel FAPI dimer [68Ga]Ga-LNC1013},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2024},
  volume = {51},
  number = {9},
  pages = {2761--2773},
  doi = {10.1007/s00259-024-06703-z}
}
Kostenlos starten →